var data={"title":"Melphalan: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Melphalan: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6523?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=melphalan-patient-drug-information\" class=\"drug drug_patient\">see &quot;Melphalan: Patient drug information&quot;</a> and <a href=\"topic.htm?path=melphalan-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Melphalan: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709032\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Bone marrow suppression: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Severe bone marrow suppression with resulting infection or bleeding may occur. Controlled trials comparing intravenous (IV) to oral melphalan have shown more myelosuppression with the IV formulation. Monitor hematologic laboratory parameters.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Secondary malignancy: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Melphalan produces chromosomal aberrations in vitro and in vivo. Melphalan should be considered potentially leukemogenic in humans.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hypersensitivity (injection):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity reactions, including anaphylaxis, have occurred in approximately 2% of patients who received the IV formulation of melphalan. Discontinue treatment with melphalan for serious hypersensitivity reactions.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Experienced physician: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Administer melphalan under the supervision of a qualified health care provider experienced in the use of cancer chemotherapeutic agents.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192382\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Alkeran;</li>\n      <li>Evomela</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192383\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Alkeran</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192432\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Alkylating Agent;</li>\n      <li>\n        Antineoplastic Agent, Alkylating Agent (Nitrogen Mustard)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192387\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Intravenous melphalan is available in different formulations. Indications for use, product preparation, storage, and dosing differ between formulations. Use caution when selecting melphalan formulations for preparation and administration. Do not mix or combine the formulations. Melphalan is associated with a moderate emetic potential (depending on dose and/or administration route); antiemetics may be recommended to prevent nausea and vomiting. Adjust dose based on patient response and weekly blood counts.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Multiple myeloma (conditioning regimen prior to hematopoietic stem cell transplantation):</b> IV (Evomela only): 100 mg/m<sup>2</sup> daily for 2 days on day -3 and day -2 prior to autologous stem cell transplantation on day 0 (Hari 2015). <b>Note:</b> Per the manufacturer, if patients weigh more than 130% of their ideal body weight, body surface area should be calculated using adjusted ideal body weight.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Multiple myeloma conditioning regimen for autologous hematopoietic stem cell transplantation (off-label doses):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/m<sup>2</sup> alone 2 days prior to transplantation (Fermand 2005; Moreau 2002) <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">140 mg/m<sup>2</sup> 2 days prior to transplantation (combined with busulfan) (Fermand 2005) <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">140 mg/m<sup>2</sup> 2 days prior to transplantation (combined with total body irradiation [TBI]) (Moreau 2002) <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">140 mg/m<sup>2</sup> 5 days prior to transplantation (combined with TBI) (Barlogie 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Multiple myeloma (palliative treatment):</b> <b>Note:</b> Response is gradual; may require repeated courses to realize benefit:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral: Usual dose (as described in the manufacturer&rsquo;s labeling):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">6 mg once daily for 2 to 3 weeks initially, followed by up to 4 weeks rest, then a maintenance dose of 2 mg daily as hematologic recovery begins <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">10 mg daily for 7 to 10 days; institute 2 mg daily maintenance dose after WBC &gt;4,000 cells/mm<sup>3</sup> and platelets &gt;100,000 cells/mm<sup>3</sup> (~4 to 8 weeks); titrate maintenance dose to hematologic response <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">0.15 mg/kg/day for 7 days, with a 2 to 6 week rest, followed by a maintenance dose of &le;0.05 mg/kg/day as hematologic recovery begins  <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">0.25 mg/kg/day for 4 days (or 0.2 mg/kg/day for 5 days); repeat at 4- to 6-week intervals as ANC and platelet counts return to normal</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Other dosing regimens in <b>combination therapy</b> (off-label doses):</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">4 mg/m<sup>2</sup>/day for 7 days every 4 weeks (in combination with prednisone <b>or</b> with prednisone and thalidomide) (Palumbo 2006; Palumbo 2008) <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">6 mg/m<sup>2</sup>/day for 7 days every 4 weeks (in combination with prednisone) (Palumbo 2004)  <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">0.25 mg/kg/day for 4 days every 6 weeks (in combination with prednisone [Facon 2006; Facon 2007] <b>or</b> with prednisone and thalidomide [Facon 2007]) <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">9 mg/m<sup>2</sup>/day for 4 days every 6 weeks (in combination with prednisone <b>or</b> with prednisone and bortezomib) (Dimopoulos 2009; San Miguel 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV (Alkeran and Evomela): 16 mg/m<sup>2</sup> administered at 2-week intervals for 4 doses, then  administer at 4-week intervals after adequate hematologic recovery.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Ovarian cancer:</b> Oral: 0.2 mg/kg/day for 5 days, repeat every 4 to 5 weeks <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Off-label dosing: 7 mg/m<sup>2</sup>/day in 2 divided doses for 5 days, repeat every 28 days (Wadler 1996)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Amyloidosis, light chain (off-label use):</b> Oral: 0.22 mg/kg/day for 4 days every 28 days (in combination with oral dexamethasone) (Palladini 2004) <b>or</b> 10 mg/m<sup>2</sup>/day for 4 days every month (in combination with oral dexamethasone) for 12 to 18 treatment cycles (Jaccard 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">\n      <b>Hodgkin lymphoma, relapsed/refractory (off-label use):</b> IV: 30 mg/m<sup>2</sup> over 15 minutes on day 6 (in combination with carmustine, etoposide, and cytarabine [mini-BEAM regimen]); repeat cycle every 4 to 6 weeks (Colwill 1995; Martin 2001)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192411\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=melphalan-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Melphalan: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Intravenous melphalan is available in different formulations. Indications for use, product preparation, storage, and dosing differ between formulations. Use caution when selecting melphalan formulations for preparation and administration. Do not mix or combine the formulations. Melphalan is associated with a moderate emetic potential (depending on dose and/or administration route); antiemetics may be recommended to prevent nausea and vomiting (Dupuis 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">\n      <b>Conditioning regimen for autologous hematopoietic stem cell transplantation (off-label use):</b>  IV: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">140 mg/m<sup>2</sup> 2 days prior to transplantation (combined with busulfan) (Canete 2009)  <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">180 mg/m<sup>2</sup> (with pre- and posthydration) 12 to 30 hours prior to transplantation (Pritchard 2005) <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">45 mg/m<sup>2</sup>/day for 4 days starting 8 days prior to transplantation (combined with busulfan or etoposide and carboplatin) (Berthold 2005) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192388\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. Use caution and begin at the lower end of dosing range.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192389\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">The manufacturer's labeling contains the following adjustment recommendations (for approved dosing levels) based on route of administration:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral: Moderate to severe renal impairment: Consider a reduced dose initially.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Conditioning regimen for multiple myeloma: No dosage adjustment is necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Palliative treatment of multiple myeloma: BUN &ge;30 mg/dL: Reduce dose by up to 50%.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">Hemodialysis: Melphalan is not removed (to any significant degree) by hemodialysis. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <i>The following adjustments have also been recommended:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aronoff 2007: Adults: Oral (based on a 6 mg once-daily dose):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">CrCl 10 to 50 mL/minute: Reduce dose to 75% of normal dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">CrCl &lt;10 mL/minute: Reduce dose to 50% of normal dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Hemodialysis: Administer dose after hemodialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Continuous ambulatory peritoneal dialysis (CAPD): Reduce dose to 50% of normal dose. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Continuous renal replacement therapy (CRRT): Reduce dose to 75% of normal dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Carlson 2005: Oral (for melphalan-prednisone combination therapy; based on a study evaluating toxicity with melphalan dosed at 0.25 mg/kg/day for 4 days/cycle):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">CrCl &gt;10 to &lt;30 mL/minute: Reduce dose to 75% of normal dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">CrCl &le;10 mL/minute: Data is insufficient for a recommendation</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kintzel 1995:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Oral: Adjust dose in the presence of hematologic toxicity</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">CrCl 46 to 60 mL/minute: Reduce dose to  85% of normal dose.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">CrCl 31 to 45 mL/minute: Reduce dose to  75% of normal dose.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">CrCl &lt;30 mL/minute: Reduce dose to  70% of normal dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Badros 2001: IV: Autologous stem cell transplant (single-agent conditioning regimen; no busulfan or irradiation): Serum creatinine &gt;2 mg/dL: Reduce dose from 200 mg/m<sup>2</sup> over 2 days (as 100 mg/m<sup>2</sup>/day for 2 days) to 140 mg/m<sup>2</sup> given as  a single-dose infusion</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">International Myeloma Working Group (IMWG) Recommendations (Dimopoulos 2016):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">The IMWG recommends the use of the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (preferred) or the Modification of Diet in Renal Disease (MDRD) formula to evaluate renal function estimation in multiple myeloma patients with a stable serum creatinine. </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">CrCl &gt;60 mL/minute: Usual dose: 0.15 to 0.25 mg/kg/day for 4 to 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">CrCl 15 to 59 mL/minute: Reduce dose to 75% of usual dose </p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">CrCl &lt;15 mL/minute: Reduce dose to 50% of usual dose </p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">Hemodialysis: Reduce dose to 50% of usual dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">IV (high-dose melphalan for autologous stem cell transplant conditioning regimen):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">CrCl &gt;60 mL/minute: Usual dose: 200 mg/m<sup>2</sup> per treatment course</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">CrCl &lt;15 to 59 mL/minute: Reduce dose to 140 mg/m<sup>2</sup> per treatment course; 100 mg/m<sup>2</sup> (per treatment course) may be appropriate in some patients</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">Hemodialysis: Reduce dose to 100 to 140 mg/m<sup>2</sup> per treatment course </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5528483\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Melphalan is hepatically metabolized; however, dosage adjustment does not appear to be necessary (King, 2001).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20344392\" class=\"block doo drugH1Div\"><span class=\"drugH1\">Dosing: Obesity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>American Society of Clinical Oncology (ASCO) Guidelines for appropriate chemotherapy dosing in obese adults with cancer (<b>Note:</b> Excludes HSCT dosing):</i>  Utilize patient&rsquo;s actual body weight (full weight) for calculation of body surface area- or weight-based  dosing, particularly when the intent of therapy is curative; manage regimen-related toxicities in the same manner as for nonobese patients; if a dose reduction is utilized due to toxicity, consider resumption of full weight-based dosing with subsequent cycles, especially if cause of toxicity (eg, hepatic or renal impairment) is resolved (Griggs 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>American Society for Blood and Marrow Transplantation (ASBMT) practice guideline committee position statement on chemotherapy dosing in obesity:</i> Utilize actual body weight (full weight) for calculation of body surface area in melphalan dosing for hematopoietic stem cell transplant conditioning regimens in adults (Bubalo 2014). <b>Note:</b> The manufacturer of Evomela recommends that if patients weigh more than 130% of their ideal body weight, body surface area should be calculated using adjusted ideal body weight.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10146784\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">WBC &lt;3000/mm<sup>3</sup>: Withhold treatment until recovery</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Platelets &lt;100,000/mm<sup>3</sup>: Withhold treatment until recovery</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">IV: Palliative treatment of multiple myeloma: Adjust dose based on blood cell count at the nadir and day of treatment</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192358\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Alkeran: 50 mg (1 ea) [contains alcohol, usp, propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Evomela: 50 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Alkeran: 2 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192342\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46443778\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Different formulations of intravenous melphalan are available. Alkeran (melphalan hydrochloride for injection) and generic melphalan hydrochloride are reconstituted with the supplied diluent (which contains propylene glycol and ethanol). Evomela (melphalan for injection) is reconstituted with normal saline. Use caution when selecting melphalan formulations for preparation and administration. Do not mix or combine the formulations.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192362\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Melphalan is associated with a moderate emetic potential (depending on dose and/or administration route); antiemetics may be recommended to prevent nausea and vomiting (Dupuis 2011).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Intravenous melphalan is available in different formulations. Indications for use, product preparation, storage, and dosing differ between formulations. Use caution when selecting melphalan formulations for preparation and administration. Do not mix or combine the formulations.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">Oral: Administer on an empty stomach (Schmidt 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IV: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Alkeran: Due to limited stability, complete administration of IV dose should occur within 60 minutes of reconstitution. Infuse over 15 to 20 minutes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Evomela: Infuse over 15 to 20 minutes (palliative treatment for multiple myeloma) or 30 minutes (conditioning regimen for autologous stem cell transplantation).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Melphalan (IV) is an irritant; local reactions may occur (Perez Fidalgo 2012). Extravasation may cause local tissue damage; administration by slow injection into a fast running IV solution into an injection port or via a central line is recommended; do not administer by direct injection into a peripheral vein.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132804\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]). </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules. For IV preparation, NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs). Double gloving, a gown, and (if dosage form allows) CSTDs are required during IV administration (NIOSH 2016).  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192361\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Multiple myeloma:</b> Palliative treatment of multiple myeloma (injection [Alkeran and Evomela] and tablets); high-dose conditioning treatment prior to hematopoietic stem cell transplantation (HSCT) (Evomela only).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ovarian cancer:</b> Palliative treatment of nonresectable epithelial ovarian carcinoma (tablets)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25730741\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Amyloidosis, light chain; Autologous stem cell transplantation conditioning regimen (pediatrics); Hodgkin lymphoma, relapsed/refractory</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192441\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Melphalan may be confused with Mephyton, Myleran</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Alkeran may be confused with Alferon, Leukeran, Myleran</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error. </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Different formulation issues: Intravenous melphalan is available in different formulations. Evomela (melphalan for injection) is a lyophilized powder which is reconstituted with normal saline to a 5 mg/mL concentration. Alkeran (melphalan hydrochloride for injection) and generic melphalan hydrochloride are also powder formulations which are reconstituted with the supplied diluent (which contains propylene glycol and ethanol) to a 5 mg/mL concentration. Indications for use, product preparation, storage, and dosing differ between formulations. Use caution when selecting melphalan formulations for preparation and administration. Do not mix or combine the formulations.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192349\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Peripheral edema (conditioning: 33%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (&ge;50%; conditioning: 77%), dizziness (conditioning: 38%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypokalemia (&ge;50% conditioning: 74%), hypophosphatemia (conditioning: 49%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (&ge;50%; conditioning: 93%), nausea (&ge;50%; conditioning: 90%), vomiting (&ge;50%; conditioning: 64%), decreased appetite (conditioning: 49%), constipation (conditioning: 48%), mucositis (conditioning: 38%), abdominal pain (conditioning: 28%), dysgeusia (conditioning: 28%), stomatitis (conditioning: 28%), dyspepsia (conditioning: 26%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (&ge;50%), decreased absolute lymphocyte count (&ge;50%), decreased neutrophils (&ge;50%), decreased platelet count (&ge;50%; nadir: 14 to 21 days; recovery: 28 to 35 days), decreased white blood cell count (&ge;50%; nadir: 14 to 21 days; recovery: 28 to 35 days), febrile neutropenia (conditioning: 41%; grades 3/4: 28%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (conditioning: 48%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Hematochezia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Amenorrhea (9%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hypersensitivity reaction (IV: 2%; less common in oral formula; includes bronchospasm, dyspnea, edema, hypotension, pruritus, skin rash, tachycardia, urticaria), anaphylaxis (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Renal failure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Vasculitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Flushing sensation, tingling sensation</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: SIADH (dose related; Greenbaum-Lefkoe 1985)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Infertility, inhibition of testicular function</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Bone marrow depression</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Hepatic sinusoidal obstruction syndrome (formerly known as hepatic veno-occlusive disease), hepatitis, increased serum transaminases, jaundice</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased blood urea nitrogen</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Chromosomal abnormality</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Alopecia, bone marrow failure (irreversible), hemolytic anemia, interstitial pneumonitis, maculopapular rash, pulmonary fibrosis, skin ulceration at injection site, tissue necrosis at injection site (rarely requiring skin grafting)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192365\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to melphalan or any component of the formulation; patients whose disease was resistant to prior melphalan therapy (Alkeran only).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192346\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Bone marrow suppression: <b>[US Boxed Warning]: Bone marrow suppression is common; may be severe and result in infection or bleeding; has been demonstrated more with the IV formulation (compared to oral). </b> Myelosuppression is dose-related; myeloablation is expected when used in high doses for conditioning regimens prior to stem cell transplantation. Do not administer melphalan-containing conditioning regimen unless the stem cell product is available for rescue. Monitor blood counts; supportive care for infections, anemia, and thrombocytopenia may be necessary. When used for palliative treatment, may require treatment delay or dose modification for thrombocytopenia or neutropenia. Use with caution in patients with prior bone marrow suppression, impaired renal function (consider dose reduction), or who have received prior (or concurrent) chemotherapy or irradiation. Myelotoxicity is generally reversible, although irreversible bone marrow failure has been reported. In patients who are candidates for autologous transplantation, avoid melphalan-containing induction regimens if future transplant may be necessary (due to the effects on stem cell reserve).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Extravasation: Melphalan is an irritant; local reactions may occur (Perez Fidalgo 2012). Extravasation may cause local tissue damage. Administration by slow injection into a fast running IV solution into an injection port or via a central line is recommended; do not administer directly into a peripheral vein.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Fertility effects: Suppresses ovarian function and  produces amenorrhea; may also cause reversible or irreversible testicular suppression.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Gastrointestinal toxicity: Gastrointestinal toxicities, including nausea, vomiting, diarrhea, and mucositis are common, particularly when used in high doses for conditioning regimens (the incidence of grade 3 or 4 mucositis was 13% in clinical trials). When administering high-dose melphalan in autologous transplantation, cryotherapy is recommended to prevent oral mucositis (Lalla 2014). Melphalan is associated with a moderate emetic potential (depending on dose and/or administration route); antiemetics may be recommended to prevent nausea and vomiting (Dupuis 2011). Nutritional support and/or analgesics may be necessary in patients with severe mucositis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatotoxicity: Abnormal liver function tests may occur; hepatitis and jaundice have also been reported. Hepatic sinusoidal obstruction syndrome (SOS; formerly called veno-occlusive disease [VOD]) has been reported with IV melphalan. Monitor liver function tests.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity reactions: <b>[US Boxed Warning]: Hypersensitivity reactions (including anaphylaxis) have occurred in ~2% of patients receiving IV melphalan,</b> usually after multiple treatment cycles. Symptoms may include urticaria, pruritus, edema, skin rashes, tachycardia, bronchospasm, dyspnea, and hypotension. Discontinue infusion and treat symptomatically. Hypersensitivity may also occur (rarely) with oral melphalan. Do not readminister (oral or IV) in patients who experience hypersensitivity to melphalan.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pulmonary toxicity: Pulmonary fibrosis (some fatal) and interstitial pneumonitis have been observed with treatment. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Secondary malignancy: <b>[US Boxed Warning]: Produces chromosomal abnormalities in vitro and in vivo. Melphalan should be considered potentially leukemogenic in humans.</b> Secondary malignancies (including acute myeloid leukemia, myeloproliferative disease, and carcinoma) have been reported (some patients were receiving combination chemotherapy or radiation therapy); the risk is increased with increased treatment duration and cumulative doses.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Dosage reduction is recommended with IV melphalan in patients with renal impairment (when used for palliative treatment); reduced initial doses may also be recommended with oral melphalan. Closely monitor patients with azotemia. High-dose melphalan with autologous stem cell transplant is feasible in patients with multiple myeloma and renal impairment (Dimopoulos 2016).  Prolonged mucositis has occurred when standard melphalan doses were administered to patients with chronic kidney disease (Bodge 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: Toxicity may be increased in elderly; start with lowest recommended adult doses.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Formulations: Intravenous melphalan is available in different formulations. Evomela (melphalan for injection) is a lyophilized powder which is reconstituted with normal saline to a 5 mg/mL concentration. Alkeran (melphalan hydrochloride for injection) and generic melphalan hydrochloride are also powder formulations which are reconstituted with the supplied diluent (which contains propylene glycol and ethanol) to a 5 mg/mL concentration. Indications for use, product preparation, storage, and dosing differ between formulations. Use caution when selecting melphalan formulations for preparation and administration. Do not mix or combine the formulations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP 1997; Zar 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Experienced physician: <b>[US Boxed Warning]: Should be administered under the supervision of an experienced cancer chemotherapy physician. </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Immunizations: Avoid vaccination with live vaccines during treatment if immunocompromised.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299659\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192351\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9605&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carmustine: Melphalan may enhance the adverse/toxic effect of Carmustine. Specifically, melphalan may sensitize patients to carmustine lung toxicity. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Melphalan may enhance the nephrotoxic effect of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nalidixic Acid: May enhance the adverse/toxic effect of Melphalan. Necrotic enterocolitis has been reported in pediatric patients.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192378\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Food interferes with oral absorption. Management: Administer on an empty stomach.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192354\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3034719\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse effects have been observed in animal reproduction studies. May cause fetal harm if administered during pregnancy. Women of reproductive potential should be advised to avoid pregnancy while on and after melphalan therapy. Males with female partners of reproductive potential should use effective contraception during and after melphalan treatment. Therapy may suppress ovarian function leading to amenorrhea. Reversible and irreversible testicular suppression has been reported in male patients after melphalan administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13265279\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if melphalan is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, breast-feeding is not recommended by the manufacturer.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192356\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential and platelet count, serum electrolytes, renal/liver function tests, serum uric acid; signs/symptoms of hypersensitivity reaction, pulmonary toxicity, and gastrointestinal toxicity; monitor infusion site.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192345\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Alkylating agent which is a derivative of mechlorethamine that inhibits DNA and RNA synthesis via formation of carbonium ions; cross-links strands of DNA; acts on both resting and rapidly dividing tumor cells.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192364\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Variable and incomplete </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 0.5 L/kg; Evomela: Penetrates CSF; Alkeran: Low penetration into CSF</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~50% to 92%; primarily to albumin (~40% to 60%), ~20% to alpha<sub>1</sub>-acid glycoprotein </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic; chemical hydrolysis to monohydroxymelphalan and dihydroxymelphalan</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral: Variable; 56% to 93%; exposure is reduced by 36% to 54% with a high-fat meal</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Terminal: IV: ~75 minutes; Oral: 1.5 &plusmn; 0.83 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Oral: ~1 to 2 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Oral: Feces (20% to 50%); urine (~10% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192367\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Alkeran Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (1): $1,971.72</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Evomela Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (1): $2,400.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Melphalan HCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (1): $1,971.72</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Alkeran Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (50): $679.22</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Melphalan Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (50): $610.62</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192369\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Alkeran (AE, AT, AU, BB, BE, BF, BH, BJ, BR, CH, CI, CL, CN, CR, CY, CZ, DE, DK, DO, EE, EG, ET, FI, FR, GB, GH, GM, GN, GR, GT, HK, HN, HR, HU, ID, IE, IL, IN, IQ, IR, IS, IT, JO, KE, KR, KW, LB, LR, LT, LU, LV, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NI, NL, NO, NZ, OM, PA, PH, PL, PT, QA, RU, SA, SC, SD, SE, SG, SI, SK, SL, SN, SV, SY, TH, TN, TR, TW, TZ, UA, UG, UY, VN, YE, ZA, ZM, ZW);</li>\n      <li>Alkerana (AR);</li>\n      <li>Alphalan (LK);</li>\n      <li>Melfalan (ES);</li>\n      <li>Melpha (PK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alberts DS, Chang SY, Chen HS, et al, &ldquo;Oral Melphalan Kinetics,&rdquo; <i>Clin Pharmacol Ther</i>, 1979, 26(6):737-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/melphalan-drug-information/abstract-text/498715/pubmed\" target=\"_blank\" id=\"498715\">498715</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alkeran (melphalan injection) [prescribing information]. Research Triangle Park, NJ: GlaxoSmithKline; February 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alkeran (melphalan tablets) [prescribing information]. Research Triangle Park, NJ: GlaxoSmithKline; June 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 100.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Badros A, Barlogie B, Siegel E, et al, &ldquo;Results of Autologous Stem Cell Transplant in Multiple Myeloma Patients With Renal Failure,&rdquo; <i>Br J Haematol</i>, 2001, 114(4):822-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/melphalan-drug-information/abstract-text/11564069/pubmed\" target=\"_blank\" id=\"11564069\">11564069</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barlogie B, Kyle RA, Anderson KC, et al, &ldquo;Standard Chemotherapy Compared With High-Dose Chemoradiotherapy for Multiple Myeloma: Final Results of Phase III US Intergroup Trial S9321,&rdquo; <i>J Clin Oncol</i>, 2006, 24(6):929-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/melphalan-drug-information/abstract-text/16432076/pubmed\" target=\"_blank\" id=\"16432076\">16432076</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16129365\"></a>Berthold F, Boos J, Burdach S, et al, &ldquo;Myeloablative Megatherapy With Autologous Stem-Cell Rescue Versus Oral Maintenance Chemotherapy as Consolidation Treatment in Patients With High-Risk Neuroblastoma: A Randomised Controlled Trial,&rdquo; <i>Lancet Oncol</i>, 2005, 6(9):649-58.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/melphalan-drug-information/abstract-text/16129365/pubmed\" target=\"_blank\" id=\"16129365\">16129365</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bodge MN, Reddy S, Thompson MS, Savani BN. Preparative regimen dosing for hematopoietic stem cell transplantation in patients with chronic kidney disease: analysis of the literature and recommendations. <i>Biol Blood Marrow Transplant</i>. 2014;20(7):908-919.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/melphalan-drug-information/abstract-text/24565993/pubmed\" target=\"_blank\" id=\"24565993\">24565993</a>]</span><span class=\"doi\">10.1016/j.bbmt.2014.02.013</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bubalo J, Carpenter PA, Majhail N, et al.  Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee. <i>Biol Blood Marrow Transplant</i>. 2014;20(5):600-616.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/melphalan-drug-information/abstract-text/24462742/pubmed\" target=\"_blank\" id=\"24462742\">24462742</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19171715\"></a>Canete A, Gerrard M. Rubie H, et al, &ldquo;Poor Survival for Infants with MYCN-Amplified Metastatic Neuroblastoma Despite Intensified Treatment: The International Society for Paediatric Oncology European Neuroblastoma Experience,&rdquo; <i>J Clin Oncol</i>, 2009, 27(7):1014-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/melphalan-drug-information/abstract-text/19171715/pubmed\" target=\"_blank\" id=\"19171715\">19171715</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Carlson K, Hjorth M, Knudsen LM, et al, &ldquo;Toxicity in Standard Melphalan-Prednisone Therapy Among Myeloma Patients With Renal Failure - A Retrospective Analysis and Recommendations for Dose Adjustment,&rdquo; <i>Br J Haematol</i>, 2005, 128(5):631-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/melphalan-drug-information/abstract-text/15725084/pubmed\" target=\"_blank\" id=\"15725084\">15725084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"7844600\"></a>Colwill R, Crump M, Couture F, et al, &ldquo;Mini-BEAM as Salvage Therapy for Relapsed or Refractory Hodgkin&rsquo;s Disease Before Intensive Therapy or Autologous Bone Marrow Transplantation,&rdquo; <i>J Clin Oncol</i>, 1995, 13(2):396-402.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/melphalan-drug-information/abstract-text/7844600/pubmed\" target=\"_blank\" id=\"7844600\">7844600</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dimopoulos MA, Richardson PG, Schlag R, et al, &ldquo;VMP (Bortezomib, Melphalan, and Prednisone) is Active and Well Tolerated in Newly Diagnosed Patients With Multiple Myeloma With Moderately Impaired Renal Function, and Results in Reversal of Renal Impairment: Cohort Analysis of the Phase III VISTA Study,&rdquo; <i>J Clin Oncol</i>, 2009, 27(36):6086-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/melphalan-drug-information/abstract-text/19858394/pubmed\" target=\"_blank\" id=\"19858394\">19858394</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dimopoulos MA, Sonneveld P, Leung N, et al. International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment. <i>J Clin Oncol</i>. 2016;34(13):1544-1557.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/melphalan-drug-information/abstract-text/26976420/pubmed\" target=\"_blank\" id=\"26976420\">26976420</a>]</span><span class=\"doi\">10.1200/JCO.2015.65.0044</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Sung L, et al; Pediatric Oncology Group of Ontario. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2011;57(2):191-198.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/melphalan-drug-information/abstract-text/21465637/pubmed\" target=\"_blank\" id=\"21465637\">21465637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Holdsworth M, et al; Pediatric Oncology Group of Ontario. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2013;60(7):1073-1082.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/melphalan-drug-information/abstract-text/23512831/pubmed\" target=\"_blank\" id=\"23512831\">23512831</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Evomela (melphalan) [prescribing information]. Irvine, CA: Spectrum Pharmaceuticals, Inc; March 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Facon T, Mary JY, Hulin C, et al, &ldquo;Melphalan and Prednisone Plus Thalidomide Versus Melphalan and Prednisone Alone or Reduced-Intensity Autologous Stem Cell Transplantation in Elderly Patients With Multiple Myeloma (IFM 99-06): A Randomised Trial,&rdquo; <i>Lancet</i>, 2007, 370(9594):1209-18.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/melphalan-drug-information/abstract-text/17920916/pubmed\" target=\"_blank\" id=\"17920916\">17920916</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Facon T, Mary JY, Pegourie B, et al, &ldquo;Dexamethasone-Based Regimens versus Melphalan-Prednisone for Elderly Multiple Myeloma Patients Ineligible for High-Dose Therapy,&rdquo; <i>Blood</i>, 2006, 107(4):1292-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/melphalan-drug-information/abstract-text/16174762/pubmed\" target=\"_blank\" id=\"16174762\">16174762</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fermand JP, Katsahian S, Divine M, et al, &ldquo;High-Dose Therapy and Autologous Blood Stem-Cell Transplantation Compared With Conventional Treatment in Myeloma Patients Aged 55 to 65 years: Long-Term Results of a Randomized Control Trial From the Group Myelome-Autogreffe,&rdquo; <i>J Clin Oncol</i>, 2005, 23(36):9227-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/melphalan-drug-information/abstract-text/16275936/pubmed\" target=\"_blank\" id=\"16275936\">16275936</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Greenbaum-Lefkoe B, Rosenstock JG, Belasco JB, Rohrbaugh TM, Meadows AT. Syndrome of inappropriate antidiuretic hormone secretion. A complication of high-dose intravenous melphalan. <i>Cancer</i>. 1985;55(1):44-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/melphalan-drug-information/abstract-text/3965085/pubmed\" target=\"_blank\" id=\"3965085\">3965085</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Griggs JJ, Mangu PB, Anderson H, et al, &ldquo;Appropriate Chemotherapy Dosing For Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline,&rdquo;<i> J Clin Oncol</i>, 2012, 30(13):1553-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/melphalan-drug-information/abstract-text/22473167/pubmed\" target=\"_blank\" id=\"22473167\">22473167</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hari P, Aljitawi OS, Arce-Lara C, et al. A phase IIb, multicenter, open-label, safety, and efficacy study of high-dose, propylene glycol-free melphalan hydrochloride for injection (EVOMELA) for myeloablative conditioning in multiple myeloma patients undergoing autologous transplantation. <i>Biol Blood Marrow Transplant</i>. 2015;21(12):2100-2105.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/melphalan-drug-information/abstract-text/26327631/pubmed\" target=\"_blank\" id=\"26327631\">26327631</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/melphalan-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17855669\"></a>Jaccard A, Moreau P, Leblond V, et al, &ldquo;High-Dose Melphalan versus Melphalan Plus Dexamethasone for AL Amyloidosis,&rdquo; <i>N Engl J Med</i>, 2007, 357(11):1083-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/melphalan-drug-information/abstract-text/17855669/pubmed\" target=\"_blank\" id=\"17855669\">17855669</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    King PD and Perry MC, &ldquo;Hepatotoxicity of Chemotherapy,&rdquo; <i>Oncologist</i>, 2001, 6(2):162-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/melphalan-drug-information/abstract-text/11306728/pubmed\" target=\"_blank\" id=\"11306728\">11306728</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kintzel PE and Dorr RT, &ldquo;Anticancer Drug Renal Toxicity and Elimination: Dosing Guidelines for Altered Renal Function,&rdquo; <i>Cancer Treat Rev</i>, 1995, 21(1):33-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/melphalan-drug-information/abstract-text/7859226/pubmed\" target=\"_blank\" id=\"7859226\">7859226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lalla RV, Bowen J, Barasch A, et al; Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO). MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. <i>Cancer</i>. 2014;120(10):1453-1461.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/melphalan-drug-information/abstract-text/24615748/pubmed\" target=\"_blank\" id=\"24615748\">24615748</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11328296\"></a>Martin A, Fernandez-Jimenez MC, Caballero MD, et al, &ldquo;Long-Term Follow-Up in Patients Treated with Mini-BEAM as Salvage Therapy for Relapsed or Refractory Hodgkin&rsquo;s Disease,&rdquo; <i>Br J Haematol</i>, 2001, 113(1):161-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/melphalan-drug-information/abstract-text/11328296/pubmed\" target=\"_blank\" id=\"11328296\">11328296</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moreau P, Facon T, Attal M, et al, &ldquo;Comparison of 200 mg/m<sup>2</sup> Melphalan and 8 Gy Total Body Irradiation Plus 140 mg/m<sup>2</sup> Melphalan as Conditioning Regimens for Peripheral Blood Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma: Final Analysis of the Intergroupe Francophone du My&eacute;lome 9502 Randomized Trial,&rdquo; <i>Blood</i>, 2002, 99(3):731-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/melphalan-drug-information/abstract-text/11806971/pubmed\" target=\"_blank\" id=\"11806971\">11806971</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nath CE, Shaw PJ, Montgomery K, et al, &ldquo;Population Pharmacokinetics of Melphalan in Pediatric Blood or Marrow Transplant Recipients,&rdquo; <i>Br J Clin Pharmacol</i>, 2007, 64(2):151-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/melphalan-drug-information/abstract-text/17324241/pubmed\" target=\"_blank\" id=\"17324241\">17324241</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nath CE, Shaw PJ, Trotman J, et al, &ldquo;Population Pharmacokinetics of Melphalan in Patients With Multiple Myeloma Undergoing High Dose Therapy,&rdquo;  <i>Br J Clin Pharmacol</i>, 2010, 69(5):484-97.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/melphalan-drug-information/abstract-text/20573084/pubmed\" target=\"_blank\" id=\"20573084\">20573084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15070667\"></a>Palladini G, Perfetti V, Obici L, et al, &ldquo;Association of Melphalan and High-Dose Dexamethasone is Effective and Well Tolerated in Patients With AL (Primary) Amyloidosis Who are Ineligible for Stem Cell Transplantation,&rdquo; <i>Blood</i>, 2004, 103(8):2936-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/melphalan-drug-information/abstract-text/15070667/pubmed\" target=\"_blank\" id=\"15070667\">15070667</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Palumbo A, Bringhen S, Caravita T, et al, &ldquo;Oral Melphalan and Prednisone Chemotherapy Plus Thalidomide Compared With Melphalan and Prednisone Alone in Elderly Patients With Multiple Myeloma: Randomised Controlled Trial,&rdquo; <i>Lancet</i>, 2006, 367(9513):825-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/melphalan-drug-information/abstract-text/16530576/pubmed\" target=\"_blank\" id=\"16530576\">16530576</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Palumbo A, Bringhen S, Liberati AM, et al, &ldquo;Oral Melphalan, Prednisone, and Thalidomide in Elderly Patients With Multiple Myeloma: Updated Results of a Randomized Controlled Trial,&rdquo; <i>Blood</i>, 2008, 112(8):3107-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/melphalan-drug-information/abstract-text/18505783/pubmed\" target=\"_blank\" id=\"18505783\">18505783</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Palumbo A, Bringhen S, Petrucci MT, et al, &ldquo;Intermediate-Dose Melphalan Improves Survival of Myeloma Patients Aged 50 to 70: Results of a Randomized Controlled Trial,&rdquo; <i>Blood</i>, 2004, 104(10):3052-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/melphalan-drug-information/abstract-text/15265788/pubmed\" target=\"_blank\" id=\"15265788\">15265788</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    P&eacute;rez Fidalgo JA, Garc&iacute;a Fabregat L, Cervantes A, et al. Management of chemotherapy extravasation: ESMO-EONS clinical practice guidelines. <i>Ann Oncol</i>. 2012;23(Suppl 7):vii167-173.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/melphalan-drug-information/abstract-text/22997449/pubmed\" target=\"_blank\" id=\"22997449\">22997449</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pinguet F, Martel P, Rouanet P, et al, &ldquo;Effect of Sodium Chloride Concentration and Temperature on Melphalan Stability During Storage and Use,&rdquo; <i>Am J Hosp Pharm</i>, 1994, 51(21):2701-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/melphalan-drug-information/abstract-text/7856585/pubmed\" target=\"_blank\" id=\"7856585\">7856585</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15546135\"></a>Pritchard J, Cotterill SJ, Germond SM, et al, &ldquo;High Dose Melphalan in the Treatment of Advanced Neuroblastoma: Results of a Randomised Trial (ENSG-1) by the European Neuroblastoma Study Group,&rdquo; <i>Pediatr Blood Cancer</i>, 2005, 44(4):348-57.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/melphalan-drug-information/abstract-text/15546135/pubmed\" target=\"_blank\" id=\"15546135\">15546135</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roila F, Herrstedt J, Aapro M, et al; ESMO/MASCC Guidelines Working Group. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. <i>Ann Oncol</i>. 2010;21(suppl 5):v232-v243.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/melphalan-drug-information/abstract-text/20555089/pubmed\" target=\"_blank\" id=\"20555089\">20555089</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    San Miguel JF, Schlag R, Khuageva NK, et al, &ldquo;Bortezomib Plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma,&rdquo; <i>New Engl J Med</i>, 2008, 359(9):906-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/melphalan-drug-information/abstract-text/18753647/pubmed\" target=\"_blank\" id=\"18753647\">18753647</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schmidt LE, Dalhoff K. Food-drug interactions. <i>Drugs</i>. 2002;62(10):1481-1502.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/melphalan-drug-information/abstract-text/12093316/pubmed\" target=\"_blank\" id=\"12093316\">12093316</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schuh A, Dandridge J, Haydon P, et al, &ldquo;Encephalopathy Complicating High-Dose Melphalan,&rdquo; <i>Bone Marrow Transplant</i>, 1999, 24(10):1141-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/melphalan-drug-information/abstract-text/10578165/pubmed\" target=\"_blank\" id=\"10578165\">10578165</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Seddon BM, Cassoni AM, Galloway MJ, et al, &ldquo;Fatal Radiation Myelopathy After High-Dose Busulfan and Melphalan Chemotherapy and Radiotherapy for Ewing&rsquo;s Sarcoma: A Review of the Literature and Implications for Practice,&rdquo; <i>Clin Oncol</i>, 2005, 17(5):385-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/melphalan-drug-information/abstract-text/16097572/pubmed\" target=\"_blank\" id=\"16097572\">16097572</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wadler S, Yeap B, Vogl S, et al, &ldquo;Randomized Trial of Initial Therapy With Melphalan Versus Cisplatin-Based Combination Chemotherapy in Patients With Advanced Ovarian Carcinoma: Initial and Long Term Results -- Eastern Cooperative Oncology Group Study E2878,&rdquo; <i>Cancer</i>, 1996, 77(40):733-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/melphalan-drug-information/abstract-text/8616766/pubmed\" target=\"_blank\" id=\"8616766\">8616766</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/melphalan-drug-information/abstract-text/17555487/pubmed\" target=\"_blank\" id=\"17555487\">17555487</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9605 Version 165.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709032\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F192382\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F192383\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F192432\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F192387\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F192411\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F192388\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F192389\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F5528483\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Obesity\" href=\"#F20344392\" class=\"outlineLink\">Dosing: Obesity</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F10146784\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F192358\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F192342\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F46443778\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F192362\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132804\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F192361\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25730741\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F192441\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F192349\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F192365\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F192346\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299659\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F192351\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F192378\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F192354\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F3034719\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F13265279\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F192356\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F192345\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F192364\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F192367\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F192369\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9605|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=melphalan-patient-drug-information\" class=\"drug drug_patient\">Melphalan: Patient drug information</a></li><li><a href=\"topic.htm?path=melphalan-pediatric-drug-information\" class=\"drug drug_pediatric\">Melphalan: Pediatric drug information</a></li></ul></div></div>","javascript":null}